Key data includes ASCO oral presentation of data from the Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 trial in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma DUBLIN
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Oral Presentation of Interim Data from the AURELIO-03 Study of SOT101 at the 2022 ASCO Annual MeetingSOTIO will share interim safety and efficacy results from SOTIO’s AURELIO-03 study on Saturday, June 4AURELIO-03 is a Phase 1/1b dose escalation study of the interleukin-15 superagonist SOT101 as monotherapy an.